Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DHA:IBNSINA's 5-Year Yield-on-Cost % is ranked worse than 54.47% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.335
vs DHA:IBNSINA: 1.99
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
The IBN SINA Pharmaceutical Industry 5-Year Yield-on-Cost % Related Terms
DHA:IBNSINA vs IMNPQ: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The IBN SINA Pharmaceutical Industry's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The IBN SINA Pharmaceutical Industry 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The IBN SINA Pharmaceutical Industry's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where The IBN SINA Pharmaceutical Industry's 5-Year Yield-on-Cost % falls into.
The IBN SINA Pharmaceutical Industry 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a 5-Year Yield-on-Cost % of 1.99 as of Jul. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. According to the industry distribution chart, The IBN SINA Pharmaceutical Industry ranks #280 out of 514 companies in the Drug Manufacturers industry, placing it in the top 54.5%.
Is The IBN SINA Pharmaceutical Industry's 5-Year Yield-on-Cost % too high?
The IBN SINA Pharmaceutical Industry's current 5-Year Yield-on-Cost % is 1.99. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.34. The IBN SINA Pharmaceutical Industry's value of 1.99 is 14.8% below this industry median. Based on the distribution chart, The IBN SINA Pharmaceutical Industry ranks #280 out of 514 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's 5-Year Yield-on-Cost % compare to IMNPQ?
According to the Drug Manufacturers industry distribution chart, The IBN SINA Pharmaceutical Industry ranks #280 out of 514 companies for 5-Year Yield-on-Cost %. This places The IBN SINA Pharmaceutical Industry in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. The IBN SINA Pharmaceutical Industry's value of 1.99 is 14.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.34, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The IBN SINA Pharmaceutical Industry's current 5-Year Yield-on-Cost % of 1.99 is 14.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The IBN SINA Pharmaceutical Industry's current 5-Year Yield-on-Cost % is 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a current 5-Year Yield-on-Cost % of 1.99. The current 5-Year Yield-on-Cost % is 1.99 and 14.8% below the Drug Manufacturers industry median of 2.34. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current 5-Year Yield-on-Cost % is 1.99 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The IBN SINA Pharmaceutical Industry Business Description
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
20GF Score
Get the complete analysis for DHA:IBNSINA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBNSINA has been successfully added to your 
